AcuCort

AcuCort Liabilities

The The Liabilities of AcuCort (ACUC.SL) as of Nov 21, 2026 is 4.42 M SEK. In the previous year, The Liabilities was 10.98 M SEK — a change of -59.70% (lower).

Liabilities

4.42 MSEK

YoY

-59.70%

Last updated:

In 2024, AcuCort's total liabilities amounted to 4.42 M SEK, a -59.70% difference from the 10.98 M SEK total liabilities in the previous year.

The AcuCort Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
1.74 M SEK
Jan 1, 2018
1.90 M SEK
Jan 1, 2019
2.02 M SEK
Jan 1, 2020
1.10 M SEK
Jan 1, 2021
2.83 M SEK
Jan 1, 2022
4.12 M SEK
Jan 1, 2023
10.98 M SEK
Jan 1, 2024
4.42 M SEK
The AcuCort Liabilities history
YEARLiabilitiesYoY
4.42 MSEK-59.70%
10.98 MSEK+166.19%
4.12 MSEK+45.79%
2.83 MSEK+157.32%
1.10 MSEK-45.54%
2.02 MSEK+6.15%
1.90 MSEK+9.25%
1.74 MSEK+190.48%
599,000.00SEK+22.24%
490,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcuCort Stock analysis

What does AcuCort do? AcuCort AB is a pharmaceutical company based in Lund, Sweden, operating within the Health Care sector. The company focuses on the development, marketing, and sale of oral dissolvable films, specifically targeting medical applications. Its primary product, ISICORT, utilizes dexamethasone, a glucocorticoid, for treating acute allergic reactions and managing nausea and vomiting associated with chemotherapy. AcuCort AB has a small operational footprint, employing four full-time staff members. The company completed its initial public offering (IPO) on April 24, 2017, and is listed under the ticker ACUC.SL with ISIN SE0009695927. It maintains a website at https://acucort.se/ for further information. AcuCort AB operates predominantly in the Nordic region, with its headquarters situated in Lund, Skåne. The company's business model centers on the production and distribution of specialized pharmaceutical products designed to address specific medical needs. While details about its financial performance, market share, or additional product lines are not provided, the company's focus remains on its core product and regional market presence. Its operational scale reflects a startup or early-stage pharmaceutical enterprise with limited resources. The company's website serves as the primary source for updates and corporate information. AcuCort AB's activities are confined to the development and commercialization of oral film technology, emphasizing targeted therapeutic applications in healthcare. AcuCort is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing AcuCort's Liabilities

AcuCort's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AcuCort's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing AcuCort's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

AcuCort's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in AcuCort’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about AcuCort stock

The Liabilities of AcuCort is 4.42 M SEK in 2024.

The Liabilities of AcuCort changed from 10.98 M SEK to 4.42 M SEK, representing a -59.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities AcuCort since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's AcuCort historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AcuCort

All Key Metrics — AcuCort